
Catena Biosciences
Catena Biosciences is a YC Summer 2021 (S21) company. Based in Berkeley, CA, USA. Team of 7.
About Catena Biosciences
Summary
Catena Biosciences builds a protein conjugation platform that links any two soluble proteins together using a naturally occurring cysteine-tyrosine bond, without restricting payload size or complexity. The platform replaces conventional antibody-drug conjugate chemistry, which is limited to single small-molecule payloads and unstable linkers, by enabling multi-payload conjugates with precise site control and greater bond stability. Current work targets solid tumors, with the underlying technology also applied to CRISPR proteins, cancer antibodies, and cell surfaces across oncology, vaccines, and inflammatory disease.
From the Y Combinator listing
Using protein coupling to build new therapies
Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.
Facts
- Healthcare / Healthcare -> Therapeutics
- Berkeley, CA, USA
- 7
- Active
- Early
Founders (2)
- Marco Lobba
- Matthew Francis
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works